The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1509
Sublingual Nitroglycerin Powder (GoNitro)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved a sublingual powder formulation of nitroglycerin (GoNitro – Espero) for prevention or acute relief of an attack of angina pectoris. It is the first powder formulation of nitroglycerin to become available in the US. Most patients with angina use sublingual nitroglycerin tablets (Nitrostat, and generics). Translingual spray formulations of nitroglycerin (NitroMist, Nitrolingual Pumpspray, and generics) are also available.1

CLINICAL STUDIES — In an unpublished, randomized, double-blind, crossover trial in 51 patients with exertional angina pectoris (summarized in the package insert), doses of nitroglycerin powder ranging from 200-1600 mcg produced significant, dose-related increases in exercise tolerance, time to onset of angina, and time to ST-segment depression, compared to placebo. No clinical studies comparing nitroglycerin ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Sublingual Nitroglycerin Powder (GoNitro)
Article code: 1509d
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian